For: | Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 2017; 23(24): 4317-4323 [PMID: 28706414 DOI: 10.3748/wjg.v23.i24.4317] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v23/i24/4317.htm |
Number | Citing Articles |
1 |
Theresa Watts, Diane Lauver, Ajay K. Sethi, Traci Snedden, Susan Zahner. Hepatitis C virus infections among people aged 15–44, United States, 2009–2018. Public Health Nursing 2021; 38(2): 167 doi: 10.1111/phn.12808
|
2 |
Pearson Balatow, Amber Sandlin, Theodore James Cory. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. Expert Opinion on Pharmacotherapy 2021; 22(14): 1839 doi: 10.1080/14656566.2021.1943359
|
3 |
Kazuo Notsumata, Yoshimoto Nomura, Akihiro Tanaka, Yoshikatsu Nomura, Teruyuki Ueda, Taku Sanada, Hiroyuki Watanabe, Daisyu Toya. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study. Internal Medicine 2020; 59(20): 2457 doi: 10.2169/internalmedicine.4445-20
|
4 |
Nathalia Alves Araujo de Almeida, Jose Junior F de Barros, Catarina Goes de Santana, Natalia Spitz , Leticia Bomfim Campos, Marcia Amendola Pires, Carlos Eduardo Brandao Mello, Vanessa Salete de Paula. Evaluation of Occult Hepatitis B Infection in Individuals with Chronic Hepatitis C Before Treatment with Oral Direct-Acting Antivirals. Hepatitis Monthly 2019; (In Press) doi: 10.5812/hepatmon.92317
|
5 |
Noha H. Habashy, Marwa M. Abu-Serie. Major royal-jelly protein 2 and its isoform X1 are two novel safe inhibitors for hepatitis C and B viral entry and replication. International Journal of Biological Macromolecules 2019; 141: 1072 doi: 10.1016/j.ijbiomac.2019.09.080
|
6 |
Yasuhito Tanaka, Daisuke Nakamoto, Yi Piao, Hajime Mizutani, Ryozo Wakabayashi, Yoshiyuki Saito, Kyung min Kwon, Harriet Dickinson. Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy. Infectious Diseases and Therapy 2024; 13(7): 1607 doi: 10.1007/s40121-024-00997-0
|
7 |
Helen S. Te, Dong Heun Lee, Ann E. Woolley, Maheen Z. Abidi, Cynthia Fisher, Marty T. Sellers, Sarah Taimur, Taylor Livelli, Tamika Watkins, Dzhuliyana Handarova, Gerald J. Berry, Riki Graves, Chak‐Sum Ho, Anna L. Hughart, Michelle Kittleson, Charles C. Marboe, Rachel A. Miller, Tanvi S. Sharma, Anil J. Trindade, R. Patrick Wood, Lorenzo N. Zaffiri, Stephanie M. Pouch, Lara Danziger‐Isakov. Hepatitis B transmission/reactivation associated with Hepatitis B core antibody and Hepatitis C nucleic acid testing positive organs: A report from the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee. Transplant Infectious Disease 2024; doi: 10.1111/tid.14305
|
8 |
Ekram W. Abd El‐Wahab, Mohammed Metwally, Nesma Lotfy. Effectiveness of hepatitis B vaccination in chronic HCV patients after successful generic direct acting antiviral therapy: significance of isolated hepatitis B core antibodies. Tropical Medicine & International Health 2021; 26(8): 882 doi: 10.1111/tmi.13588
|
9 |
Arkadiusz Urbanowicz, Radosław Zagożdżon, Michał Ciszek. Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy. Archivum Immunologiae et Therapiae Experimentalis 2019; 67(2): 79 doi: 10.1007/s00005-018-0532-8
|
10 |
Beshoy T. Yanny, Nyan L. Latt, Sammy Saab, Steven Han, Gina Choi, Jason Kramer, Amandeep K. Sahota. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Journal of Clinical Gastroenterology 2018; 52(10): 908 doi: 10.1097/MCG.0000000000000986
|
11 |
Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar AC, Sanjay Hadigal. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World Journal of Gastroenterology 2019; 25(29): 3897-3919 doi: 10.3748/wjg.v25.i29.3897
|
12 |
Isabela Gomes Ribeiro, Jordana Grazziela Alves Coelho-dos-Reis, Jordana Rodrigues Barbosa Fradico, Ismael Artur da Costa-Rocha, Luciana Diniz Silva, Lucy Ana dos Santos Fonseca, Rhaissa Carvalho Said Stancioli, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho, Rosângela Teixeira. Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy. Antiviral Research 2021; 190: 105073 doi: 10.1016/j.antiviral.2021.105073
|
13 |
Nathália Alves Araujo de Almeida, Vanessa Salete de Paula. Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review. Journal of Applied Microbiology 2022; 132(3): 1616 doi: 10.1111/jam.15351
|
14 |
Niloofar Naderi, Ghazal Masoudi, Bita Behnava, Seyed Moayed Alavian, Soyar Sari, Ali Anvar, Alireza Azizi Saraji, Ali Namvar, Azam Bolhassani. Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents. Hepatitis Monthly 2018; (In Press) doi: 10.5812/hepatmon.83337
|
15 |
Edward John Gane, Michael R. Charlton, Rosmawati Mohamed, Jose Decena Sollano, Kyaw Soe Tun, Thuy Thi Thu Pham, Diana Alcantara Payawal, Rino Alvani Gani, David Handojo Muljono, Subrat Kumar Acharya, Hui Zhuang, Akash Shukla, Kaushal Madan, Neeraj Saraf, Satyendra Tyagi, Karam Romeo Singh, Ian Homer Yee Cua, Ganbolor Jargalsaikhan, Davadoorj Duger, Wattana Sukeepaisarnjaroen, Hery Djagat Purnomo, Irsan Hasan, Laurentius Adrianto Lesmana, Cosmas Rinaldi Adithya Lesmana, Khin Pyone Kyi, Win Naing, Allampura Chandrashekar Ravishankar, Sanjay Hadigal. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource‐limited settings. Journal of Viral Hepatitis 2020; 27(5): 466 doi: 10.1111/jvh.13244
|
16 |
Imre Kovesdi, Tibor Bakacs. Therapeutic Exploitation of Viral Interference. Infectious Disorders - Drug Targets 2020; 20(4): 423 doi: 10.2174/1871526519666190405140858
|
17 |
Rashed Abdelaal, Beshoy Yanny, Mohamed El Kabany. HBV/HCV Coinfection in the Era of HCV-DAAs. Clinics in Liver Disease 2019; 23(3): 463 doi: 10.1016/j.cld.2019.04.003
|